Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:clinicalTrialPhase |
Phase 1/2
|
| gptkbp:developedBy |
gptkb:Stoke_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
STX-478
|
| gptkbp:indication |
gptkb:Dravet_syndrome
epilepsy |
| gptkbp:intendedUse |
treatment of Dravet syndrome
|
| gptkbp:mechanismOfAction |
selective inhibition of Nav1.1 protein degradation
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:SCN1A_gene
|
| gptkbp:bfsParent |
gptkb:Scorpion_Therapeutics
|
| gptkbp:bfsLayer |
7
|